Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
Subscribe To Our Newsletter & Stay Updated